|
Título:
|
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial
|
|
Autores:
|
St-Jean, Pamela-L. ;
Xue, Zhengyu ;
Carter, Nick ;
Koh, Gavin-C. K. W. ;
Duparc, Stephan ;
Taylor, Maxine ;
Beaumont, Claire ;
Llanos-Cuentas, Alejandro ;
Rueangweerayut, Ronnatrai ;
Krudsood, Srivicha ;
Green, Justin-A. ;
Rubio, Justin-P.
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
BMC, 2019-02-06T14:48:06Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
BACKGROUND: Tafenoquine (TQ) and primaquine (PQ) are 8-aminoquinolines (8-AQ) with anti-hypnozoite activity against vivax malaria. PQ is the only FDA-approved medicine for preventing relapsing Plasmodium vivax infection and TQ is currently in phase 3 clinical trials for the same indication. Recent studies have provided evidence that cytochrome P450 (CYP) metabolism via CYP2D6 plays a role in PQ efficacy against P. vivax and have suggested that this effect may extend to other
|
|
En línea:
|
http://doi.org/10.1186/s12936-016-1145-5
|
